Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710470 · ClinicalTrials.gov registry record
A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
A clinical trial of Psoriasis, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 833
- Enrollment target
- 1
- Study location
NCT06710470 is a study of Psoriasis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 833 participants, above the 482-participant average among 125 other Psoriasis trials with a reported enrollment target (73% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06710470, a study of Psoriasis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 833 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.
Conditions Studied
Interventions
- DRUG Deucravacitinib
- DRUG Systemic psoriasis medications
- OTHER No systemic medications
Study Locations (1)
New Jersey
- Bristol-Meyers Squibb - Lawrenceville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 833 participants |
| Start Date | 2024-08-02 |
| Est. Completion | 2029-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06710470
The ClinicalTrials.gov registry entry for NCT06710470 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 833 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 482-participant average among 125 other Psoriasis trials with a reported enrollment target (73% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Deucravacitinib is the first listed.
NCT06710470 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06710470 about?
NCT06710470 is a clinical study titled "A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring". This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.
What is the current status of trial NCT06710470?
This trial is currently active not recruiting. The enrollment target is 833 participants. The study started on 2024-08-02. Estimated completion is 2029-02-28.
What conditions does trial NCT06710470 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT06710470?
The interventions under investigation include: Deucravacitinib (DRUG), Systemic psoriasis medications (DRUG), No systemic medications (OTHER).
Who is sponsoring clinical trial NCT06710470?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710470 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.